The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTWhy Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?Jan ReedijkView Author Information Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands Cite this: Chem. Rev. 1999, 99, 9, 2499–2510Publication Date (Web):August 21, 1999Publication History Received16 February 1999Revised25 May 1999Published online21 August 1999Published inissue 8 September 1999https://pubs.acs.org/doi/10.1021/cr980422fhttps://doi.org/10.1021/cr980422fresearch-articleACS PublicationsCopyright © 1999 American Chemical SocietyRequest reuse permissionsArticle Views3207Altmetric-Citations690LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antineoplastic agents,Genetics,Ligands,Peptides and proteins,Platinum Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnson, A. P. (2024) · Being and Becoming Teachers of Writing · doi:10.4324/9781003334798-34 · Cited by 4,502
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Self-citationTakahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
Hayes, D. M., Cvitkovic, E., Golbey, R. B., Scheiner, E., Helson, L., & Krakoff, I. H. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j · Cited by 626
Improved understanding in platinium antitumour chemistry
Reedijk, J. (1996) · Chemical Communications · doi:10.1039/cc9960000801 · Cited by 589
Self-citationCisplatin and DNA repair in cancer chemotherapy
Zamble, D. B., & Lippard, S. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89095-7 · Cited by 538
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
Cited by
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Zhou, W., Saran, R., & Liu, J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00063 · Cited by 931
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Fuertes, M. A., Alonso, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 893
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Porous Hollow Fe3O4 Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin
Cheng, K., Peng, S., Xu, C., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja903300f · Cited by 438
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes
Hall, M. D., Telma, K. A., Chang, K.-E., Lee, T. D., Madigan, J. P., Lloyd, J. R., Goldlust, I. S., Hoeschele, J. D., & Gottesman, M. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0247 · Cited by 377
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340
Hydrolysis Theory for Cisplatin and Its Analogues Based on Density Functional Studies
Zhang, Y., Guo, Z., & You, X.-Z. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0023938 · Cited by 317
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Self-citationNucleic Acid Recognition by Metal Complexes of Bleomycin
Claussen, C. A., & Long, E. C. (1999) · Chemical Reviews · doi:10.1021/cr980449z · Cited by 276
Human Copper Transporters: Mechanism, Role in Human Diseases and Therapeutic Potential
Gupta, A., & Lutsenko, S. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.84 · Cited by 275
Metadata
- Authors
- Reedijk, J.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-08-21
- Volume
- 99
- Issue
- 9
- Pages
- 2499-2510
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2017030176
- Cited by
- 771
- References
- 27
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
